Navigation Links
Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function
Date:1/8/2009

tes from discovery into the clinic."

Principal investigator Osama Gaber, M.D., F.A.C.S. Director, Transplant Center of Excellence at The Methodist Hospital, Houston, Texas said, "Our clinical team is excited to participate in clinical trials that evaluate new therapies for renal transplant patients. Patients that develop DGF following renal transplantation have inferior kidney graft survival compared to those who do not. There is a real unmet medical need for a drug product to prevent DGF."

Daniel Zurr, Chief Executive Officer, commented, "We are very pleased to announce initiation of human dosing of the systemically administered QPI-1002 in our Phase I/II trial in kidney transplant patients. Furthermore, our siRNA drug candidate, PF-4523655, has been advanced into two Phase II clinical trials -- one for diabetic macular edema and the other for age related macular degeneration -- by our licensee, Pfizer. In addition, we recently announced that our QPI-1007 drug candidate, utilizing a novel siRNA structure developed by Quark, is being evaluated in advanced IND-enabling preclinical studies as a neuroprotective agent for eye diseases. These significant developments confirm the robustness of Quark's clinical pipeline and the strength of its capabilities in the RNAi arena."

Delayed graft function (DGF) is one of the most common complications during the immediate postoperative period in renal transplantation and affects 25-40% of the deceased donor renal transplants in the United States. DGF in renal transplantation results most often from ischemia-reperfusion injury that occurs when the blood flow is re-established to the transplanted kidney initiating a chain of events that can lead to severe renal damage upon transplantation. Post-kidney transplant DGF is associated with longer hospital stays and higher rates of graft rejection, which in turn decreases the survival of the transplanted kidney (graft survival). Current
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy
2. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
3. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
4. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
5. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
6. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
7. Quark Pharmaceuticals Appoints New Chief Medical Officer
8. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
9. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... SAN DIEGO , Oct. 20, 2014 /PRNewswire/ ... development of therapeutic antibodies, today announced the appointment ... Development Officer. Dr. Londei will lead the preclinical ... "We are pleased to welcome ... Hamza Suria , President and Chief Executive ...
(Date:10/20/2014)... , Oct. 20, 2014 Lpath, ... leader in bioactive lipid-targeted therapeutics, received official notification from ... been granted another key patent supporting its iSONEP™ ... issued patent, European patent No. 2087002, claims compositions ... in Lpath,s two lead compounds, iSONEP and ASONEP. ...
(Date:10/20/2014)... , Oct. 20, 2014   Mary,s Medicinals ... for Caring, is a 4-Star Sponsor of Operation ... Veterans with unique products, programs and services to assist ... freedom. Key Facts: , An ... is a safe and effective treatment for pain, Post-traumatic ...
Breaking Medicine Technology:AnaptysBio Appoints Dr. Marco Londei to Newly Created Chief Development Officer Position Clinical Immunologist to Lead AnaptysBio's Pipeline Advancement 2Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 2Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 3Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 4Mary's Medicinals Announces 4-Star Sponsorship of Operation Grow4Vets 2Mary's Medicinals Announces 4-Star Sponsorship of Operation Grow4Vets 3
... Calif. , June 30 Xoft, the ... that Hoag Breast Care Center of Hoag Memorial Hospital ... installed an Axxent® Electronic Brachytherapy, eBx™ System to support ... as part of its progressive, comprehensive approach to breast ...
... WILMINGTON, Del. , June 29 AstraZeneca (NYSE: ... District Court, District of Delaware , has found that the substance patent ... ruling, the court found that no inequitable conduct was committed by any Shionogi ... reissued. , , , ...
Cached Medicine Technology:Hoag Breast Care Center Installs Xoft Electronic Brachytherapy System for IORT Program 2Hoag Breast Care Center Installs Xoft Electronic Brachytherapy System for IORT Program 3Hoag Breast Care Center Installs Xoft Electronic Brachytherapy System for IORT Program 4CRESTOR® Patent Upheld By US Court 2CRESTOR® Patent Upheld By US Court 3
(Date:10/20/2014)... Unveiled at the Sept. 18 board meeting, The Center ... hospital ROI on membership dues at 12.5. In other words, ... in value to member hospitals. The calculation used to determine ... , “This is the first time we’ve actually been ... methodology is really sound,” said Bill Ryan , president ...
(Date:10/20/2014)... Do you ever feel difficulty in ... wonderful app Metassessor for teachers, specialists and parents. SIMpalm, ... its client “Intervention Development LLC” to launch Metassessor App ... for iOS 4.3 or later and is Compatible with ... for iPhone 5. It is now available on Apple ...
(Date:10/19/2014)... Dr. Babatunde Osotimehin, Executive Director of ... a ceasefire agreement that is expected to lead to ... were kidnapped from the north-eastern Nigerian town of Chibok—the ... enough, and it is high time they are returned ... , "We owe it to these girls to positively ...
(Date:10/19/2014)... Recently, Fancyflyingfox.com, an innovative company that ... announced its latest designs of 2014 mother of ... elegant outfits are offered with big discounts, up to ... October 30 can enjoy this special offer. , ... it has become one of the leading brands in ...
(Date:10/19/2014)... 19, 2014 (HealthDay News) -- New stem cell-based research ... to new treatments, a new study suggests. Scientists ... intestinal tissue in a lab dish. They then transplanted ... studying intestinal disorders, according to the researchers. "This ... and conditions that can cause intestinal failure, from genetic ...
Breaking Medicine News(10 mins):Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3Health News:Fancyflyingfox.com Updates Its Website With New Mother Of The Bride Dresses For 2014 2Health News:Scientists Grow, Implant Human Intestinal Tissue in Mice 2
... detection system finds cavities before X-rays allowing, ... filling required, TORONTO, July 3 /PRNewswire/ - ... its breakthrough technology which,detects and monitors the early ... x-rays. It reduces the number of invasive and ...
... Utah, July 3 Nu Skin Enterprises, Inc.,(NYSE: ... presenting at the,Oppenheimer Consumer Growth Conference in Boston on ... webcast live beginning at 2:55 p.m.,(EST). Those wishing to ... Nu Skin Enterprises, website, at, http://www.nuskinenterprises.com . The archive ...
... DETROIT, July 2 The Michigan Attorney General announced,on ... Cross Blue Shield of,Michigan challenging a capital transaction between ... taken the position that BCBSM is not,authorized by Public ... in fact, Accident Fund obtained prior regulatory approval for ...
... General Hospital (MGH) investigators have shown that an MGH-developed, ... the bloodstream can be used to determine the genetic ... for targeted treatment and monitoring genetic changes that occur ... called the CTC-chip will appear in the July 24 ...
... light of today,s,announcement that Attorney General Mike Cox is ... the Coalition for a Fair and,Competitive Insurance Market is ... Blue Cross Blue Shield of Michigan (BCBSM) to use ... and insurance., "We were confident when we raised ...
... individual patients, study says , , WEDNESDAY, July 2 (HealthDay News) ... cells in the blood of lung cancer patients may make ... the genetic "signature" of particular tumors but to monitor changes ... think this is key to personalized medicine," said Dr. Daniel ...
Cached Medicine News:Health News:Breakthrough Technology That Will Revolutionize the Treatment of Tooth Decay 2Health News:Breakthrough Technology That Will Revolutionize the Treatment of Tooth Decay 3Health News:Circulating tumor cells can reveal genetic signature of dangerous lung cancers 2Health News:Circulating tumor cells can reveal genetic signature of dangerous lung cancers 3Health News:Coalition Calls on MI Legislature to Abandon Blue Cross Legislation 2Health News:Circulating Tumor Cells Reveal Insights Into Lung Cancers 2Health News:Circulating Tumor Cells Reveal Insights Into Lung Cancers 3
... The Eppendorf Reference Series 2000 Pipette is ... stroke, a compact and robust design, and ... is used to operate the measuring stroke ... tip. Product features:Eppendorf "pipette/tip" system ensures utmost ...
... Hamilton is precision, ergonomics, and ... hand fatigue with soft non-slip, contoured ... with smooth, light plunger spring action ... and sterilization without the need for ...
This fixed-volume digital micropipet is used to accurately measure and transfer 20 microliters of solution....
... The Research Family includes fixed-volume, ... as the electronic Eppendorf Research pro ... button, these compact, high-performance pipettes have ... Optimally suited for use with original ...
Medicine Products: